To further verify the protective property of Azilsartan against endothelial dysfunction, more adhesion molecules (such as VCAM-1 and ICAM-1) and chemokines (such as CXCL2 and CCL2), as well as inflammatory factors (such as IL-6, TNF-α) will be introduced into the analysis system in our future work. This evidence concerns the gene ICAM1 and endothelial dysfunction.